Cargando…

Strategic Insight into the Combination Therapies for Metastatic Colorectal Cancer

Colorectal cancer (CRC) is the second most common cause of cancer-related deaths worldwide. The 5-year survival rate after curative resection is almost 80%, however, it is still less than satisfactory for metastatic CRC (mCRC). The combination approach including surgery, chemotherapy, molecular targ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kano, Yoshihito, Suenaga, Mitsukuni, Uetake, Hiroyuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10378516/ https://www.ncbi.nlm.nih.gov/pubmed/37504340 http://dx.doi.org/10.3390/curroncol30070480

Ejemplares similares

Comparison between three oxaliplatin-based regimens with bevacizumab in patients with metastatic colorectal cancer
por: Ohhara, Yoshihito, et al.
Publicado: (2015)

Comprehensive Genomic Profiling of Circulating Cell-Free DNA Distinguishes Focal MET Amplification from Aneuploidy in Diverse Advanced Cancers
por: Kumaki, Yuichi, et al.
Publicado: (2021)

Cetuximab could be more effective without prior bevacizumab treatment in metastatic colorectal cancer patients
por: Sato, Yasuyoshi, et al.
Publicado: (2015)

Anticoagulant therapy for venous thromboembolism detected by Doppler ultrasound in patients with metastatic colorectal cancer receiving bevacizumab
por: Suenaga, Mitsukuni, et al.
Publicado: (2015)

Associations between deepness of response and clinical outcomes among Japanese patients with metastatic colorectal cancer treated with second-line FOLFIRI plus cetuximab
por: Osumi, Hiroki, et al.
Publicado: (2015)

Factors Associated With Regorafenib Adherence With Metastatic Colorectal Cancer
por: Kawakami, Kazuyoshi, et al.
Publicado: (2019)

Role of targeted therapy in metastatic colorectal cancer
por: Ohhara, Yoshihito, et al.
Publicado: (2016)

Serum VEGF-A and CCL5 levels as candidate biomarkers for efficacy and toxicity of regorafenib in patients with metastatic colorectal cancer
por: Suenaga, Mitsukuni, et al.
Publicado: (2016)

A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer
por: Suenaga, Mitsukuni, et al.
Publicado: (2015)

Self-Reported Adherence to Capecitabine on XELOX Treatment as Adjuvant Therapy for Colorectal Cancer
por: Kawakami, Kazuyoshi, et al.
Publicado: (2017)

Patients’ self-reported adherence to capecitabine on XELOX treatment in metastatic colorectal cancer: findings from a retrospective cohort analysis
por: Kawakami, Kazuyoshi, et al.
Publicado: (2015)

Does anti-p53 antibody status predict for clinical outcomes in metastatic colorectal cancer patients treated with fluoropyrimidine, oxaliplatin, plus bevacizumab as first-line chemotherapy?
por: Osumi, Hiroki, et al.
Publicado: (2015)

Aflibercept with FOLFIRI in Japanese patients with metastatic colorectal cancer: results of a post-marketing surveillance
por: Watanabe, Jun, et al.
Publicado: (2022)

Emerging combination therapies for metastatic colorectal cancer – impact of trifluridine/tipiracil
por: Puthiamadathil, Jeevan M, et al.
Publicado: (2017)

Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients
por: Nakayama, Izuma, et al.
Publicado: (2017)

TAS-102 Monotherapy and Combination Therapy with Bevacizumab for Metastatic Colorectal Cancer
por: Liu, Cheng-Jiang, et al.
Publicado: (2021)

Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study
por: Suenaga, Mitsukuni, et al.
Publicado: (2015)

Comprehensive Genomic Profiling Reveals Clinical Associations in Response to Immune Therapy in Head and Neck Cancer
por: Noji, Rika, et al.
Publicado: (2022)

Efficacy and safety of bevacizumab-based combination therapy for treatment of patients with metastatic colorectal cancer
por: Xu, Ran, et al.
Publicado: (2018)

Current Targeted Therapy for Metastatic Colorectal Cancer
por: Ohishi, Tomokazu, et al.
Publicado: (2023)

Bevacizumab in the therapy for refractory metastatic colorectal cancer
por: Mulcahy, Mary F
Publicado: (2008)

A polymorphism in the cachexia-associated gene INHBA predicts efficacy of regorafenib in patients with refractory metastatic colorectal cancer
por: Miyamoto, Yuji, et al.
Publicado: (2020)

Advances and Insights of APC-Asef Inhibitors for Metastatic Colorectal Cancer Therapy
por: Yang, Xiuyan, et al.
Publicado: (2021)

Social Media and Rheumatology Societies: Strategic Insights
por: Alvarillo, Dominique, et al.
Publicado: (2022)

NOS2 polymorphisms in prediction of benefit from first-line chemotherapy in metastatic colorectal cancer patients
por: Schirripa, Marta, et al.
Publicado: (2018)

New developments in targeted therapy for metastatic colorectal cancer
por: Wong, Ambrose H. N., et al.
Publicado: (2023)

Angiogenesis in metastatic colorectal cancer and the benefits of targeted therapy
por: Sun, Weijing
Publicado: (2012)

Immunotherapies and Targeted Therapies in the Treatment of Metastatic Colorectal Cancer
por: Rawla, Prashanth, et al.
Publicado: (2019)

Targeting Metastatic Colorectal Cancer with Immune Oncological Therapies
por: Galbraith, Norman J., et al.
Publicado: (2021)

Phase II trial of biweekly cetuximab and irinotecan as third‐line therapy for pretreated KRAS exon 2 wild‐type colorectal cancer
por: Osumi, Hiroki, et al.
Publicado: (2018)

Clinical utility of polyethylene glycol conjugated granulocyte colony-stimulating factor (PEG-G-CSF) for preventing severe neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI plus bevacizumab: a single-center retrospective study
por: Kitagawa, Yusuke, et al.
Publicado: (2020)

Combined Treatment with Immunotherapy-Based Strategies for MSS Metastatic Colorectal Cancer
por: Baraibar, Iosune, et al.
Publicado: (2021)

Perioperative FOLFOX4 plus bevacizumab for initially unresectable advanced colorectal cancer (NAVIGATE-CRC-01)
por: Suenaga, Mitsukuni, et al.
Publicado: (2015)

Two Cases of Long-Term Survival of Advanced Colorectal Cancer with Synchronous Lung Metastases Treated with mFOLFOX6/XELOX + Bevacizumab
por: Ushida, Yuta, et al.
Publicado: (2018)

Safety profiles of current antiangiogenic therapies for metastatic colorectal cancer
por: Fuloria, Jyotsna
Publicado: (2012)

Metastatic Colorectal Cancer. First Line Therapy for Unresectable Disease
por: Aparicio, Jorge, et al.
Publicado: (2020)

Profile of trifluridine/tipiracil hydrochloride in the treatment of metastatic colorectal cancer: efficacy, safety, and place in therapy
por: Sunakawa, Yu, et al.
Publicado: (2017)

Potential role of PIN1 genotypes in predicting benefit from oxaliplatin- and irinotecan-based treatment in patients with metastatic colorectal cancer
por: Suenaga, Mitsukuni, et al.
Publicado: (2018)

Strategically targeting MYC in cancer
por: Posternak, Valeriya, et al.
Publicado: (2016)

Hydronephrosis Caused by Metastatic Breast Cancer
por: Sugimoto, Hitoshi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6s6idsbh498op3ub5l6cg3igoi